Short Interest in Hologic, Inc. (NASDAQ:HOLX) Grows By 94.3%

Hologic, Inc. (NASDAQ:HOLX) saw a significant growth in short interest in November. As of November 29th, there was short interest totalling 6,820,000 shares, a growth of 94.3% from the November 14th total of 3,510,000 shares. Approximately 2.6% of the shares of the stock are short sold. Based on an average trading volume of 2,319,500 shares, the short-interest ratio is presently 2.9 days.

HOLX stock traded up $0.40 during trading on Wednesday, hitting $52.60. 1,910,312 shares of the company traded hands, compared to its average volume of 1,891,214. The company has a 50-day moving average of $49.19 and a 200-day moving average of $48.71. The company has a debt-to-equity ratio of 1.32, a quick ratio of 1.26 and a current ratio of 1.68. Hologic has a 1 year low of $37.48 and a 1 year high of $53.00. The firm has a market capitalization of $13.97 billion, a PE ratio of 21.65, a P/E/G ratio of 2.22 and a beta of 0.77.

Hologic (NASDAQ:HOLX) last announced its quarterly earnings results on Wednesday, November 6th. The medical equipment provider reported $0.65 EPS for the quarter, hitting the Zacks’ consensus estimate of $0.65. Hologic had a positive return on equity of 29.67% and a negative net margin of 1.19%. The business had revenue of $865.80 million for the quarter, compared to analysts’ expectations of $846.54 million. During the same period in the previous year, the firm earned $0.58 EPS. The business’s quarterly revenue was up 6.4% on a year-over-year basis. Sell-side analysts expect that Hologic will post 2.63 EPS for the current year.

In related news, Director Christiana Stamoulis sold 12,306 shares of the firm’s stock in a transaction dated Friday, November 22nd. The stock was sold at an average price of $49.75, for a total transaction of $612,223.50. Following the transaction, the director now directly owns 49,481 shares of the company’s stock, valued at approximately $2,461,679.75. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. Also, CEO Stephen P. Macmillan sold 194,396 shares of the business’s stock in a transaction that occurred on Monday, November 11th. The stock was sold at an average price of $45.91, for a total value of $8,924,720.36. The disclosure for this sale can be found here. Insiders sold 215,481 shares of company stock valued at $9,988,288 over the last quarter. 0.90% of the stock is owned by company insiders.

Institutional investors have recently modified their holdings of the company. Nuveen Asset Management LLC raised its holdings in Hologic by 72,308.7% during the 2nd quarter. Nuveen Asset Management LLC now owns 5,304,658 shares of the medical equipment provider’s stock valued at $254,730,000 after buying an additional 5,297,332 shares during the last quarter. Point72 Asset Management L.P. increased its position in shares of Hologic by 203.5% in the second quarter. Point72 Asset Management L.P. now owns 1,056,488 shares of the medical equipment provider’s stock valued at $50,733,000 after acquiring an additional 708,361 shares during the period. Charles Schwab Investment Management Inc. raised its stake in shares of Hologic by 22.7% during the second quarter. Charles Schwab Investment Management Inc. now owns 1,960,574 shares of the medical equipment provider’s stock valued at $94,147,000 after acquiring an additional 363,053 shares during the last quarter. AQR Capital Management LLC raised its stake in shares of Hologic by 323.0% during the second quarter. AQR Capital Management LLC now owns 415,932 shares of the medical equipment provider’s stock valued at $19,973,000 after acquiring an additional 317,614 shares during the last quarter. Finally, Parnassus Investments CA raised its stake in shares of Hologic by 1.9% during the third quarter. Parnassus Investments CA now owns 15,825,872 shares of the medical equipment provider’s stock valued at $799,048,000 after acquiring an additional 300,090 shares during the last quarter. Hedge funds and other institutional investors own 94.07% of the company’s stock.

A number of research analysts have commented on HOLX shares. Argus increased their price target on shares of Hologic to $62.00 and gave the company a “buy” rating in a research report on Wednesday, August 14th. BidaskClub raised shares of Hologic from a “hold” rating to a “buy” rating in a research note on Thursday, November 28th. ValuEngine upgraded shares of Hologic from a “sell” rating to a “hold” rating in a report on Wednesday, November 20th. William Blair reaffirmed a “buy” rating on shares of Hologic in a research note on Thursday, November 21st. Finally, Zacks Investment Research raised shares of Hologic from a “hold” rating to a “buy” rating and set a $54.00 target price on the stock in a report on Friday, August 16th. One equities research analyst has rated the stock with a sell rating, five have given a hold rating and eight have assigned a buy rating to the company. The company has a consensus rating of “Buy” and a consensus price target of $51.84.

Hologic Company Profile

Hologic, Inc, a medical technology company, develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women in the United States, Europe, the Asia-Pacific, and internationally. It operates in five segments: Diagnostics, Breast Health, Medical Aesthetics, GYN Surgical, and Skeletal Health.

Featured Story: What is the significance of a dead cat bounce?

Receive News & Ratings for Hologic Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hologic and related companies with MarketBeat.com's FREE daily email newsletter.